Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Item

http://www.wikidata.org/entity/Q33369033

Q33369033

about

Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients Children's Oncology Group's 2013 blueprint for research: bone tumors Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.Osteosarcoma Overview.Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences.Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas What is the emotional acceptance after limb salvage with an expandable prosthesis?Does increased rate of limb-sparing surgery affect survival in osteosarcoma?Strategies for the targeted delivery of therapeutics for osteosarcoma.Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy.UK Guidelines for the Management of Bone Sarcomas.Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.Treatment of Bone Tumors Long-term functional outcome and quality of life following rotationplasty for treatment of malignant tumors.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.Invariant NKT cells increase drug-induced osteosarcoma cell death.Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial

P2860

Q24197545-ED7C304A-32D5-41C8-AADD-D710069116AF Q24632145-E38580BD-F545-4B5A-8091-278EF2FD4B58 Q27027664-84F1D44B-0000-4594-8068-7DE15A8CAE7A Q30999677-3592FD6D-644A-414A-9CBF-7DE4CA093A3E Q31018689-61445780-8AE0-48D3-9DB1-BDEDC6EB6FC0 Q33274572-B20CF446-6BA0-491B-9163-3968553B8B5B Q33373879-A8B57469-CFFC-48D8-B7BD-1A43D7FEAB0B Q33393253-088A88D3-7F07-4203-837C-8D35DC3478D1 Q33557868-ABC82306-4F22-41B5-B752-94D73C97045C Q33582914-B85E965B-83D6-442A-B628-AA444C023963 Q33725511-C27B5E4B-ACF8-4318-9490-70A14A57B6AF Q33776840-7DB75DEF-A629-45B3-B43B-4BFE7EC7E67D Q33779486-A3422B62-C65A-413A-8E03-6D20FA1F637A Q33854072-6005B86E-C8EF-4FAE-8FFF-C992531278CA Q34164442-8E808788-6904-4143-AFCE-A62A3EEBC728 Q34164575-687722C7-E3B0-4CA8-902A-FD487464973B Q34179495-FAECA5CD-F930-41BB-8E75-2C2EC91CF056 Q34305928-FF049443-8A35-43EE-B01D-0E61EFADAF8B Q34496992-FD63765F-30EC-4F0B-B80B-69FD6B77DED9 Q34528144-0653A8B8-C504-4DAA-B928-2C2DA1DC9CA9 Q34627906-A8D31369-3C28-4D00-9005-38EF0E52DCEB Q34628523-E280F742-A6EC-47EC-9CC6-1DDC4B124AD8 Q34629236-79B8B26D-AC0D-4CA3-8C96-854EBE34D4A5 Q34631306-87136FC3-80FC-45A4-B1DC-F5EF15517078 Q34636631-3CBF43D6-4C9B-4EA8-9A29-187EA7E35AC5 Q34991299-9BA567E0-73B1-4662-883D-D134A9F2E987 Q35005741-8EA76851-5B45-417E-8EE6-8C4B139B5E30 Q35138344-F818B906-265B-4B7A-AB12-3D2B33CEE86C Q35640471-6BFA4C36-1896-4DD9-B7D6-B3CA489FDAA9 Q35653799-6CDBB3C1-EA1F-4358-8FA1-B64BC4286E74 Q35740708-D586EA49-C47B-433F-BE0D-72BB22FD7DB8 Q35786882-2153884F-662B-4D45-88D8-1C86EA9B76AD Q35958048-6317D995-DD8D-4040-A3CB-9AEA48A2BBBB Q35958404-527BCB21-3C20-4DE9-B7AF-26F7759F6F14 Q35988850-DFBD21BC-2A6C-4EDE-9E3E-7A120FDD2381 Q36078941-6111160A-BB4E-4895-BAA0-A7491367842C Q36261555-F742062E-DBFE-402B-A1D2-8538BB986B85 Q36335326-6FB69D2D-96A7-450A-B2EF-04D0943B863F Q36446525-21F955E7-9342-43C6-88CE-1F32B5808AB6 Q36503647-9098D623-8C39-41AC-84BE-3C52C1376C59

P2860

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Item

http://www.wikidata.org/entity/Q33369033

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu